Osteocalcin-dependent and -independent metabolic dysregulation in a mouse model of Osteogenesis imperfecta

Abstract

Osteogenesis imperfecta (OI) is a rare bone fragility disorder. Previously, in a severe OI mouse model (Col1a1^Jrt/+), a sex- and age-dependent metabolic phenotype was observed, correlating with elevated levels of the bone-derived hormone osteocalcin (OCN). This hormone is known to play a crucial role in managing energy metabolism, including glucose regulation and fat mass. In fact, upon high-fat diet (HFD) exposure, OI mice developed a metabolic syndrome linked to sex and OCN. To assess OCN’s role in OI, Col1a1^Jrt/+ mice were crossed with OCN-deficient mice (Bglap). Under regular chow and HFD conditions, both OCN-dependent and OCN-independent metabolic alterations were identified. OCN-dependent processes were adipose tissue, liver, and insulin metabolism in a sex-, age-, and diet-dependent manner. OCN-independent traits included the pancreas in juvenile mice, HFD-induced pancreatic insulin levels and glucose intolerance, besides overall growth, fertility, and bone phenotype. Notably, increased juvenile energy expenditure was OCN-independent, while HFD-induced changes were OCN-driven. These findings demonstrate OCN’s role in shaping the metabolic phenotype while revealing distinct OCN-independent effects, emphasizing the complex genetic regulation of metabolism in OI.

References

[1] Castells S, et al. . Plasma osteocalcin levels in patients with osteogenesis imperfecta. J. Pediatr., 1986, 109: 88-91

[2] Cundy T, Horne A, Bolland M, Gamble G, Davidson J. Bone formation markers in adults with mild osteogenesis imperfecta. Clin. Chem., 2007, 53: 1109-1114

[3] Zheng WB, et al. . The role of osteocalcin in regulation of glycolipid metabolism and muscle function in children with osteogenesis imperfecta. Front. Endocrinol., 2022, 13 898645

[4] Kang H, Aryal ACS, Marini JC. Osteogenesis imperfecta: new genes reveal novel mechanisms in bone dysplasia. Transl. Res., 2017, 181: 27-48

[5] Lim J, Grafe I, Alexander S, Lee B. Genetic causes and mechanisms of Osteogenesis Imperfecta. Bone, 2017, 102: 40-49

[6] Tauer JT, Robinson M-E, Rauch F. Osteogenesis Imperfecta: New Perspectives From Clinical and Translational Research. JBMR®, 2019, 3e10174

[7] Veilleux LN, et al. . The functional muscle-bone unit in patients with osteogenesis imperfecta type I. Bone, 2015, 79: 52-57

[8] Jovanovic, M., Guterman-Ram, G. & Marini, J. C. Osteogenesis Imperfecta: mechanisms and signaling pathways connecting classical and rare OI types. Endocr. Rev. 43, 61–90 (2021).

[9] Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch. Dis. Child., 2002, 86: 356-364

[10] Glorieux FH, et al. . Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med., 1998, 339: 947-952

[11] Cropp GJ, Myers DN. Physiological evidence of hypermetabolism in osteogenesis imperfecta. Pediatrics, 1972, 49: 375-391

[12] Palomo, T., Glorieux, F. H., Schoenau, E. & Rauch, F. Body Composition in children and adolescents with Osteogenesis Imperfecta. J. Pediatr. 169, 232–237 (2015).

[13] Zambrano MB, Brizola ES, Refosco L, Giugliani R, Félix TM. Anthropometry, nutritional status, and dietary intake in pediatric patients with osteogenesis imperfecta. J. Am. Coll. Nutr., 2014, 33: 18-25

[14] Chagas CEA, Roque JP, Santarosa Emo Peters B, Lazaretti-Castro M, Martini LA. Do patients with osteogenesis imperfecta need individualized nutritional support?. Nutrition, 2012, 28: 138-142

[15] Lee NK, et al. . Endocrine regulation of energy metabolism by the skeleton. Cell, 2007, 130: 456-469

[16] Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. USA, 2008, 105: 5266-5270

[17] Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature, 2012, 481: 314-320

[18] Diegel CR, et al. . An osteocalcin-deficient mouse strain without endocrine abnormalities. PLoS Genet., 2020, 16: e1008361

[19] Moriishi T, et al. . Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass. PLoS Genet, 2020, 16: e1008586

[20] Moriishi T, Komori T. Lack of reproducibility in osteocalcin-deficient mice. PLoS Genet., 2020, 16: e1008939

[21] Chen F, et al. . First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome. J. Bone Miner. Res., 2014, 29: 1412-1423

[22] Boraschi-Diaz I, et al. . Metabolic phenotype in the mouse model of osteogenesis imperfecta. J. Endocrinol., 2017, 234: 279-289

[23] Tauer JT, et al. . Male but not female mice with severe osteogenesis imperfecta are partially protected from high-fat diet-induced obesity. Mol. Genet. Metab., 2021, 133: 211-221

[24] Gremminger VL, et al. . Skeletal muscle specific mitochondrial dysfunction and altered energy metabolism in a murine model (oim/oim) of severe osteogenesis imperfecta. Mol. Genet. Metab., 2021, 132: 244-253

[25] Zimmerman SM, et al. . Loss of RANKL in osteocytes dramatically increases cancellous bone mass in the osteogenesis imperfecta mouse (oim). Bone Rep., 2018, 9: 61-73

[26] Oury F, et al. . Endocrine regulation of male fertility by the skeleton. Cell, 2011, 144: 796-809

[27] Karsenty G, Oury F. Regulation of male fertility by the bone-derived hormone osteocalcin. Mol. Cell Endocrinol., 2014, 382: 521-526

[28] Paracha N, et al. . Osteocalcin improves glucose tolerance, insulin sensitivity and secretion in older male mice. Bone, 2024, 182 117048

[29] Ducy P, et al. . Increased bone formation in osteocalcin-deficient mice. Nature, 1996, 382: 448-452

[30] Tauer JT, et al. . Muscle-bone properties after prolonged voluntary wheel running in a mouse model of dominant severe osteogenesis imperfecta. J. Musculoskelet. Neuronal Interact., 2021, 21: 517-527

[31] Jung SM, Sanchez-Gurmaches J, Guertin DA. Brown Adipose Tissue Development and Metabolism. Handb. Exp. Pharmacol., 2019, 251: 3-36

[32] Wang C, Wang X, Hu W. Molecular and cellular regulation of thermogenic fat. Front. Endocrinol., 2023, 14 1215772

[33] Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutr. Res. Rev., 2010, 23: 270-299

[34] Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes, 1988, 37: 1163-1167

[35] Lackey DE, et al. . The role of dietary fat in obesity-induced insulin resistance. Am. J. Physiol. Endocrinol. Metab., 2016, 311: E989-E997

[36] Wei J, Hanna T, Suda N, Karsenty G, Ducy P. Osteocalcin promotes beta-cell proliferation during development and adulthood through Gprc6a. Diabetes, 2014, 63: 1021-1031

[37] Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone, 2012, 50: 568-575

[38] Lin X, et al. . Uncarboxylated osteocalcin enhances glucose uptake ex vivo in insulin-stimulated mouse oxidative but not glycolytic muscle. Calcif. Tissue Int., 2018, 103: 198-205

[39] Neff EP. A point on thermoneutrality for mice. Lab Anim., 2020, 49: 169-169

[40] Sabapathy T, Helmerhorst E, Ellison G, Bridgeman SC, Mamotte CD. High-fat diet induced alterations in plasma membrane cholesterol content impairs insulin receptor binding and signalling in mouse liver but is ameliorated by atorvastatin. Biochim Biophys. Acta Mol. Basis Dis., 2022, 1868 166372

[41] Pinckard KM, Stanford KI. The heartwarming effect of brown adipose tissue. Mol. Pharmacol., 2022, 102: 460-471

[42] Sanchez-Wandelmer J, et al. . Inhibition of cholesterol biosynthesis disrupts lipid raft/caveolae and affects insulin receptor activation in 3T3-L1 preadipocytes. Biochim Biophys. Acta, 2009, 1788: 1731-1739

[43] Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest., 2002, 109: 1125-1131

[44] Wang, D., Zhang, M., Xu, J. & Yang, J. Uncarboxylated Osteocalcin Decreases SCD1 by Activating AMPK to Alleviate Hepatocyte Lipid Accumulation. Molecules28, 3121 (2023).

[45] Xia M, et al. . Osteocalcin and non-alcoholic fatty liver disease: lessons from two population-based cohorts and animal models. J. Bone Miner. Res, 2021, 36: 712-728

[46] Oldknow KJ, MacRae VE, Farquharson C. Endocrine role of bone: recent and emerging perspectives beyond osteocalcin. J. Endocrinol., 2015, 225: R1-R19

[47] Pi M, Parrill AL, Quarles LD. GPRC6A mediates the non-genomic effects of steroids. J. Biol. Chem., 2010, 285: 39953-39964

[48] Diaz-Franco MC, Franco-Diaz de Leon R, Villafan-Bernal JR. OsteocalcinGPRC6A: An update of its clinical and biological multiorganic interactions (Review). Mol. Med. Rep., 2019, 19: 15-22

[49] Harada N. Role of androgens in energy metabolism affecting on body composition, metabolic syndrome, type 2 diabetes, cardiovascular disease, and longevity: lessons from a meta-analysis and rodent studies. Biosci. Biotechnol. Biochem., 2018, 82: 1667-1682

[50] Link JC, et al. . Increased high-density lipoprotein cholesterol levels in mice with XX versus XY sex chromosomes. Arterioscler. Thromb. Vasc. Biol., 2015, 35: 1778-1786

[51] Yang F, Babak T, Shendure J, Disteche CM. Global survey of escape from X inactivation by RNA-sequencing in mouse. Genome Res., 2010, 20: 614-622

[52] Brenner RE, Schiller B, Vetter U, Ittner J, Teller WM. Serum concentrations of procollagen I C-terminal propeptide, osteocalcin and insulin-like growth factor-I in patients with non-lethal osteogenesis imperfecta. Acta Paediatr., 1993, 82: 764-767

[53] Aglan MS, et al. . Anthropometric measurements in Egyptian patients with osteogenesis imperfecta. Am. J. Med. Genet. A, 2012, 158 A: 2714-2718

[54] Germain-Lee EL, et al. . Cross-sectional and longitudinal growth patterns in osteogenesis imperfecta: Implications for clinical care. Pediatr. Res., 2016, 79: 489-495

[55] Graff K, Syczewska M. Developmental charts for children with osteogenesis imperfecta, type I (body height, body weight and BMI). Eur. J. Pediatr., 2017, 176: 311-316

[56] Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics, 2003, 111: 1030-1036

[57] Watanabe G, Kawaguchi S, Matsuyama T, Yamashita T. Correlation of scoliotic curvature with Z-score bone mineral density and body mass index in patients with osteogenesis imperfecta. Spine, 2007, 32: E488-E494

[58] Rodrigo L, Perez-Martinez I. Osteogenesis imperfecta with celiac disease and type ii diabetes mellitus associated: improvement with a gluten-free diet. Case Rep. Med., 2012, 2012 813461

[59] Pua, S., Ashawesh, K., Murthy, N. P. N. & Randeva, H. in Society for Endocrinology BES. (Endocrine Abstracts).

[60] Tauer JT, Rauch F. Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta. Bone, 2019, 128 115036

[61] Ferron M, Wei J, Yoshizawa T, Ducy P, Karsenty G. An ELISA-based method to quantify osteocalcin carboxylation in mice. Biochem. Biophysical Res. Commun., 2010, 397: 691-696

[62] Tauer, J. T. & Komarova, S. V. Vol. V1 Mendeley Data, (2026).

[63] Tauer, J. T. & Komarova, S. V. Data on body mass, glucose tolerance, insulin tolerance, and adiposity of Col1a1Jrt/+ mice with regular or deficient osteocalcin on long-term low-fat and high-fat diets. Data in Brief (2026).

[64] Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX. The use of areas under curves in diabetes research. Diab. Care, 1995, 18: 245-250

[65] Cardoso FC, Sears W, LeBlanc SJ, Drackley JK. Technical note: comparison of 3 methods for analyzing areas under the curve for glucose and nonesterified fatty acids concentrations following epinephrine challenge in dairy cows. J. Dairy Sci., 2011, 94: 6111-6115

[66] Dempster DW, et al. . Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res., 2013, 28: 2-17

[67] Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinforma., 2006, 7 123

[68] Delage, C., Taib, T., Mamma, C., Lerouet, D. & Besson, V. C. Traumatic Brain Injury: An Age-Dependent View of Post-Traumatic Neuroinflammation and Its Treatment. Pharmaceutics13, 1624 (2021).

[69] Flurkey, K., M. Currer, J. & Harrison, D. E. Chapter 20 - Mouse Models in Aging Research. in The Mouse in Biomedical Research (Second Edition) (eds James G. F. et al.) 637-672 Academic Press, https://doi.org/10.1016/B978-012369454-6/50074-1 (2007).

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)(74421)

RIGHTS & PERMISSIONS

The Author(s)